GlaxoSmithKline Plc’s Advair

GlaxoSmithKline Plc’s Advair

GlaxoSmithKline/Via Bloomberg

Advair was Glaxo’s best-selling drug last year, with 5.05 billion pounds ($8 billion) in sales, split about evenly between asthma and COPD.